RetinaLogik, a Calgary-based health tech company, has achieved a significant milestone with a successful $1.1 million funding round and Health Canada’s Class II medical device approval. The company’s innovative AI-powered virtual reality (VR) eye exam platform is designed to revolutionize eye care.
RetinaLogik’s VR-AI technology allows eye care professionals to perform crucial tests, such as visual field exams, with greater efficiency and wider accessibility. The company’s portable headset, which also holds ISO-13485 and MDSAP certifications in addition to being FDA-registered, is designed to significantly streamline the testing process. This can lead to up to a 90% reduction in exam times and equipment costs compared to traditional systems, which could greatly improve access to care and make it more affordable. The device also includes multilingual support to facilitate better communication within clinics.
“Achieving these milestones represents a moment of great pride for our organization,” stated Dr. Sarhan, CEO of RetinaLogik. “We have developed a solution that not only makes eye care more efficient but also more affordable and accessible. With the backing of our investors and partners, we look forward to continuing to expand and improve the future of eye care for everyone.”
The funding round was co-led by Spring Impact Capital and UCeed Funds, both of which have been instrumental in supporting RetinaLogik’s growth. Nikhi, Operating Partner at UCeed Funds, highlighted the platform’s impact: “Over the past two years, the RetinaLogik team has developed a groundbreaking VR platform that delivers unparalleled clinical reliability.”
Graham Day, Managing Partner at Spring Impact Capital, underscored the company’s market potential: “By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are positioned to make a meaningful impact on communities while achieving commercial success.”
RetinaLogik’s development has also been supported by Alberta Innovates. Trevor Lynn, Vice President of Health at Alberta Innovates, noted the company’s success in commercializing health innovation through the Accelerating Innovations into Care (AICE) program.
With Health Canada approval now secured, RetinaLogik plans to scale its platform across North America and beyond. This expansion strategy aims to address critical gaps in vision care by facilitating earlier detection and treatment of vision-threatening conditions.
